Geron Files Shelf Registration for $150M At-The-Market Equity Program

summarizeSummary

Geron Corporation filed an automatic shelf registration statement to enable the sale of up to $150 million in common stock through an At-The-Market (ATM) offering, formalizing a capital raising program previously disclosed in its annual report.

check_boxKey Events

• ATM Equity Program Registration

  Geron Corporation filed an automatic shelf registration statement (S-3ASR) to register an At-The-Market (ATM) equity offering program, allowing the company to sell up to $150 million of its common stock from time to time through TD Securities (USA) LLC as sales agent.

• Potential Share Dilution

  The offering, if fully utilized, could result in substantial dilution for existing shareholders. The filing indicates that selling 90,909,091 shares at an assumed price of $1.65 per share would generate $150 million and result in an immediate dilution of $1.14 per share to new investors.

• Use of Proceeds

  The net proceeds from any sales under this program are intended for working capital and general corporate purposes, including support for RYTELO commercial activities, research and development, and drug product manufacturing. A portion may also be used for potential in-licensing or acquisitions.

• Prior Disclosure

  This S-3ASR filing formalizes the $150 million ATM equity program that was previously revealed in the company's Annual Report on Form 10-K, filed on the same date (March 2, 2026).

auto_awesomeAnalysis

This S-3ASR filing formally registers the $150 million At-The-Market (ATM) equity program that Geron Corporation disclosed in its 10-K annual report on the same day. While the program provides the company with a flexible mechanism to raise capital for its RYTELO commercialization, ongoing R&D, and general corporate needs, the potential issuance of up to $150 million in common stock represents a substantial potential dilution for existing shareholders. Investors should monitor the actual utilization of this program, as the timing and pricing of future share sales will impact the extent of dilution.